Search

Find exactly what you’re looking for.
Search

Service
Showing 241-252 of 252 results

WHAT EMPLOYERS NEED TO KNOW ABOUT THE LATEST LEGAL TRENDS AND CHALLENGES IN AN EVOLVING WORKPLACE Employers nationwide are experiencing new challenges due to the constant changes in our legal landscape, as well as the complex demands of an evolving workplace and work culture. In this year’s...

Saul Ewing is a proud sponsor of the M&A East Conference held by the Philadelphia Chapter of the Association of Corporate Growth. M&A East attracts top strategic and financial dealmakers as well as leading middle market advisors and provides an environment for valuable networking. The conference...

Darius Gambino with Danny Cevallos - on Andy Warhol/Prince SCOTUS Case and Copyright Law in Art Danny Cevallos guest hosts the Michael Smerconish Program where he invites Saul Ewing's Darius Gambino to talk copyright law in art and music. Original air date, 14 October 2022.

Saul Ewing LLP is proud to announce that Benchmark Litigation has recognized 32 of its partners across nine offices as Litigation Stars, Future Stars, or Labor and Employment Stars in its 2023 rankings. Benchmark examines recent casework handled by law firms and asks individual litigators to provide...

By now, business owners and their counsel have become increasingly aware of the high volume of lawsuits filed across the country alleging that commercial websites violate Title III of the Americans with Disabilities Act (ADA), and similar state and local laws, for failing to make their websites...

Supreme Court Ready to Address Affirmative Action, Religious Freedoms Rob Duston, an attorney with Saul Ewing in Washington, D.C., predicted we'll see the court reject some major precedents this fall. "They are rolling back a number of long-standing provisions and principles they have been skeptical...

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...

For More Information
Contact us